Investigation Of66Patients With Chronic Myeloid Leukemia Receiving Imatinib

Objective:To evaluate the efficacy of imatinb in treatment of chronic myeloidleukemia(CML) patients and analyse the overall suvival.Methods:66CML patientsreceiving imatinib were evluated for hematologic,cytogenetic,molecular responses andadverse events.Results:66patients were eveluated with a median follow-up duration of36.5(6~112) months.1.The rate of cumulative complete hematologic response(CHR),majorcytogenetic response(MCyR),complete cytogenetic response(CCyR) and major molecularresponse(MM0R) in chronic phase(CP) CML patients were94.5%、87.3%、78.2%and69.1%.These rates were significantly higher in patients with CP than in thosewith accelerated phase(AP) and blast crisis(BC)(P＜0.05).2.The rate of MM0R in low-riskpatients was significantly higher than high-risk patients(P=0.047).The estimated overallsurvival(OS) rate at1,2and4year for chronic phase patients were（97.7±1.1）%、（96.2±3.8）%and（90.1±6.8）%.The estimated progression-free(PFS) suvival rate at1,2and4year were（95.3±3.3）%、（83.0±6.5）%and（76.6±8.6）%.The OS rate for acceleratedphase and blast crisis patients at6,12and15months were（91.7±8）%、（75±2.5）%and（66.7±3.6）%,the rate of PFS at1and2year were（75.0±15.3）%and（60±18.2）%.The OS of patients in chronic phase who acceived CcyR and MM0R were better thanAP/BC patients.Conclusion:Treatment of CML patients in CP with imtinib can inducehigh hematologic,cytogenetic and molecular response and overall survial,but can not dosatisfactorily for patients in AP/BC.Imatinib resistance is still the maior problem in thetreatment with imatinib.